Expanding treatment horizons: pivmecillinam’s role in the management of uncomplicated urinary tract infections in women

Dear Editor, Uncomplicated urinary tract infections (UTIs), characterized by their occurrence in females without structural abnormalities of the urinary tract, are not only common but also a frequent reason for antibiotic prescription. Given that approximately half of all women will experience at least one UTI in their lifetime, the introduction of an effective new treatment option is both timely and critical1. Moreover, antimicrobial resistance and the need for surgical intervention in recurrent UTIs contribute to the increasing burden on the healthcare system2. The recent approval of pivmecillinam by the U.S. Food and Drug Administration (FDA) on 17 April 2024 marks a significant development in the landscape of UTI treatments, particularly for uncomplicated cases in adult females (Fig. 1)3. It is interesting to note that this is the only new antibiotic approved for UTI treatment by FDA in the last 2 decades. This drug works by inhibition of penicillin-binding protein 2 and is bactericidal4. Pivmecillinam’s approval was based on robust data from three controlled clinical trials, which assessed its efficacy in treating women 18 years and older5–7. These trials employed a composite measure of efficacy, combining clinical cure—defined as the resolution of symptoms present at trial entry with no new symptoms—and microbiological response, indicated by a reduction in the cultured bacteria from patients’ urine5–7. In the trial comparing pivmecillinam to placebo, a 62% composite response rate was achieved in patients treated with pivmecillinam, as opposed to just 10% in those who received the placebo7,8. In a comparative study against another oral cephalexin, pivmecillinam demonstrated a composite response rate of 72%, closely aligning with the 76% achieved by the comparator drug8. Furthermore, when compared to ibuprofen, pivmecillinam achieved a 66% response rate, significantly higher than the 22% observed in patients receiving the non-steroidal anti-inflammatory drug8.Figure 1: Pivmecillinam-drug information.The clinical trials also provided vital information on the safety profile of pivmecillinam. The most common side effects included nausea and diarrhea, typical of many antibiotics5. Importantly, pivmecillinam carries specific contraindications for patients with a history of severe hypersensitivity to beta-lactam antibacterial drugs, those with carnitine deficiency, and individuals suffering from porphyria5,8. Given these considerations, Pivya emerges as a valuable addition to our therapeutic arsenal, especially in an era where antibiotic resistance is a growing concern. Its efficacy in delivering both symptomatic relief and microbiological cure positions it as a strong candidate for first-line treatment in appropriate cases. Furthermore, it has been widely used outside the USA with demonstrable success. In conclusion, the approval of pivmecillinam represents a meaningful advancement in the management of uncomplicated UTIs in women. It not only expands the treatment options for UTI, but also minimizes the burden on the healthcare system, and indirectly reduces the need for surgical intervention. Ethical approval Ethical approval is not applicable for this correspondence article. Consent Informed consent is not applicable for this correspondence article. Sources of funding None. Author contribution A.A.: conceptualization, project administration, supervision, validation, writing-original draft and writing—review and editing. A.M.T.: supervision, validation, writing—review and editing. P.S.: supervision, validation, writing—review and editing. R.K.S.: supervision, validation, writing—review and editing. M.N.K.: supervision, validation, writing—review and editing. S.G.: supervision, validation, writing—review and editing. Q.S.Z.: supervision, validation, writing—review and editing. S.R.: supervision, validation, writing—review and editing. Conflicts of interest disclosure There are no conflicts of interest. Research registration unique identifying number (UIN) None. Guarantor Ayush Anand. Data availability statement None. Provenance and peer review Not commissioned, externally peer-reviewed.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.